Bob Baltera


Bob is an Entrepreneur-in-Residence on the Frazier Life Sciences team and a seasoned pharmaceutical executive with vast business and product management experience.

Bob joined Frazier in January 2016 and co-founded Hawkeye Therapeutics, a search company focused on in-licensing and developing high-quality assets from pharmaceutical companies. He is currently Chief Executive Officer at Frazier portfolio company Cirius Therapeutics, which is developing the next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH).

Before joining Frazier, Bob was Chief Executive Officer of Amira Pharmaceuticals until its its sale to Bristol-Myers Squibb in 2011 for $475 million . In this capacity, he was instrumental in focusing Amira's development efforts, strengthening its pipeline and forging key collaborations with partners such as GlaxoSmithKline. Previously, he held a number of senior management positions over 17 years at Amgen.

Bob serves on the board of directors for several companies and the San Diego Venture Group, and is a member of the board of trustees of the Keck Graduate Institute.

Bob earned his M.B.A. from the Anderson School at the University of California, Los Angeles; and a B.S. in microbiology and an M.S. in genetics from The Pennsylvania State University.


San Diego


University of California, Los Angeles (M.B.A.)
Pennsylvania State University (M.S., B.S.)

Year Joined



Select Investments